Findings identify Pep14 derived from Template‐2 as a lead peptide candidate for disrupting the HSP90–CDC37 interaction, however, further experimental validation is required to confirm its therapeutic potential in cancer treatment.
Abstract
The HSP90–CDC37 complex plays a key role in stabilizing multiple oncogenic client proteins, thereby sustaining cancer cell survival. However, targeting these dynamic interfaces remains challenging due to the large, shallow binding surfaces, which limit the effectiveness of conventional small‐molecule inhibitors. Peptide‐based therapeutics offer a promising alternative owing to their ability to mimic native motifs. Two continuous interfacial segments from CDC37 were extracted to construct template peptides, which were used to generate peptide libraries. A multi‐level hierarchical screening strategy was applied to evaluate 4050 and 843,750 sequences derived from Template‐1 and Template‐2, respectively, thereby prioritizing top candidates based on binding profiles and physicochemical suitability. The shortlisted peptides were further validated using the Boltz‐2 deep learning framework to enhance confidence in the predicted peptide structures and protein–peptide complexes. Binding free‐energy and molecular dynamics simulation analyses were subsequently performed to assess their interaction with HSP90. The lead peptide was then benchmarked against positive and negative controls to provide a relative assessment of its binding performance. Collectively, these findings identify Pep14 derived from Template‐2 as a lead peptide candidate for disrupting the HSP90–CDC37 interaction. However, further experimental validation is required to confirm its therapeutic potential in cancer treatment.
This study highlights MMs02350546 as a potential disruptor of HSP90–CDC37 interaction, presenting a promising therapeutic strategy against cancer via chaperone complex destabilization.
Peptide‐based inhibitors are promising tools to target challenging protein interfaces, yet improving their affinity and drug‐like properties is still a major hurdle. This holds particularly true for β‐sheet motifs with only limited strategies available to robustly stabilize their conformation. Previously, we reported l...
Michael H. N. Meulendijks, Yun Li, Frederik J. Steiner et al.· ChemistryEurope· 0 citations
Artificial intelligence‐assisted virtual screening enables identification of chemically diverse bioactive small molecules. We targeted transglutaminase 2 (TG2), a multifunctional protein associated with mesenchymal‐like features in breast cancer. Approximately 10 million compounds were screened against the catalytic si...
Carlo M. Bergamini, Niel M. Henriksen, Brianna Ryan et al.· ChemBioChem· 0 citations
INTRODUCTION/OBJECTIVE
The KRAS G12D mutation is a significant oncogenic factor that promotes cell proliferation and tumor development, particularly in pancreatic cancer. Inhibiting the mutated form of the KRAS protein is a critical strategy in cancer treatment. While molecules like MRTX1133 show promise, the limited e...
Ebru Okutan, Serra Özışık, V. Atalay· Current pharmaceutical desig...· 0 citations
The rapid advancement of AI has greatly boosted the efficiency of large‐scale lead compound screening, especially for proteins without resolved 3D structures in the PDB. However, current large structure databases cannot support efficient large‐scale screening within drug R&D cycles. Here, we propose a multistrategy c...
Ning-Yao Li, Xue-Yi Liu, Qiu-Yue Li et al.· Advanced Intelligent Discove...· 0 citations
This framework synthesizes generative protein design workflows to screen 1,758 newly designed protein binders targeting BCMA, CD19 and CD22 for efficacy in scalable protein-binding, T-cell activation and in vivo killing assays, and develops computational and experimental heuristics to overcome limitations.
Arthur Chow, Ho-Yin Chu, Ruo-Fan Li et al.· Nature Biomedical Engineerin...· 5 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.